The surprise election of Donald Trump as president has disrupted planning for industry and patient advocates alike. Companies mostly seem to think that’s a good thing, but one area where they are hoping for strong continuity is in the user fee program.
Industry and advocates outlined the topics at stake for the upcoming renewal of the Prescription Drug User Fee Act (PDUFA) during the Nov. 15 Rare Disease Congressional Caucus, pinning patient...